Global Primary Antibodies

Primary Antibodies Comprehensive Study by Type (Monoclonal Antibodies, Polyclonal Antibodies), Application (Proteomics, Drug Development, Genomics), End-users (Pharmaceutical and Biotechnological Companies, Academic and Research Institutes, Contract Research Organizations), Technology (Immunohistochemistry, Immunofluorescence, Western Blotting, Flow Cytometry, Immunoprecipitation, ELISA, Other Technologies), Research Area (Infectious Diseases, Immunology, Oncology, Stem Cells, Neurobiology, Others), Source (Mouse, Rabbit, Goat, Other Sources) Players and Region - Global Market Outlook to 2026

Primary Antibodies Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Primary Antibodies Market?

A primary antibody is an immunoglobulin that specifically binds to a particular protein or other biomolecule of research interest, with high specificity and affinity, for the purpose of purifying or detecting and measuring it. These antibodies can raised against any antigen of research interest, including: proteins, carbohydrates, peptides, and other small molecules. Primary antibodies are the important tools to analyse analyse components of living cells at the molecular level and identify proteins that may be involved in or may cause disease.

The market study is being classified by Type (Monoclonal Antibodies and Polyclonal Antibodies), by Application (Proteomics, Drug Development and Genomics) and major geographies with country level break-up.

Becton, Dickinson and Company (United States), Bio-Rad Laboratories (United States), Cell Signaling Technology (United States), Thermo Fisher Scientific (United States), Merck Group (Germany), Abcam plc (United Kingdom), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (United States), Agilent Technologies (United States), PerkinElmer (United States), Lonza (Switzerland), GenScript (China), BioLegend (United States), Omega BioTek (United States), Dovetail Genomics (United States) and Atlas Antibodies (Sweden) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Illumia (United States), ImmonoPresice Antibodies (Canada), Fujirebio (Sweden) and Analytik Jena AG (Germany).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Primary Antibodies market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Primary Antibodies market by Type, Application and Region.

On the basis of geography, the market of Primary Antibodies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rise in the Number of Stell Cell and Neurology Research
  • Increased Prevalence of Neurogenerative Diseases

Market Trend
  • Increased Research and Development Activities

Restraints
  • Quality Concerns and a Lack of Reproducible Results

Opportunities
  • Growth in the Healthcare Sector
  • Increased Government Funding for Research

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Primary Antibodies Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Polyclonal Antibodies
By Application
  • Proteomics
  • Drug Development
  • Genomics
By End-users
  • Pharmaceutical and Biotechnological Companies
  • Academic and Research Institutes
  • Contract Research Organizations

By Technology
  • Immunohistochemistry
  • Immunofluorescence
  • Western Blotting
  • Flow Cytometry
  • Immunoprecipitation
  • ELISA
  • Other Technologies

By Research Area
  • Infectious Diseases
  • Immunology
  • Oncology
  • Stem Cells
  • Neurobiology
  • Others

By Source
  • Mouse
  • Rabbit
  • Goat
  • Other Sources

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the Number of Stell Cell and Neurology Research
      • 3.2.2. Increased Prevalence of Neurogenerative Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Primary Antibodies, by Type, Application, End-users, Technology, Research Area, Source and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Primary Antibodies (Value)
      • 5.2.1. Global Primary Antibodies by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Polyclonal Antibodies
      • 5.2.2. Global Primary Antibodies by: Application (Value)
        • 5.2.2.1. Proteomics
        • 5.2.2.2. Drug Development
        • 5.2.2.3. Genomics
      • 5.2.3. Global Primary Antibodies by: End-users (Value)
        • 5.2.3.1. Pharmaceutical and Biotechnological Companies
        • 5.2.3.2. Academic and Research Institutes
        • 5.2.3.3. Contract Research Organizations
      • 5.2.4. Global Primary Antibodies by: Technology (Value)
        • 5.2.4.1. Immunohistochemistry
        • 5.2.4.2. Immunofluorescence
        • 5.2.4.3. Western Blotting
        • 5.2.4.4. Flow Cytometry
        • 5.2.4.5. Immunoprecipitation
        • 5.2.4.6. ELISA
        • 5.2.4.7. Other Technologies
      • 5.2.5. Global Primary Antibodies by: Research Area (Value)
        • 5.2.5.1. Infectious Diseases
        • 5.2.5.2. Immunology
        • 5.2.5.3. Oncology
        • 5.2.5.4. Stem Cells
        • 5.2.5.5. Neurobiology
        • 5.2.5.6. Others
      • 5.2.6. Global Primary Antibodies by: Source (Value)
        • 5.2.6.1. Mouse
        • 5.2.6.2. Rabbit
        • 5.2.6.3. Goat
        • 5.2.6.4. Other Sources
      • 5.2.7. Global Primary Antibodies Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Primary Antibodies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Becton, Dickinson and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio-Rad Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cell Signaling Technology (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck Group (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abcam plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Danaher Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Agilent Technologies (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. PerkinElmer (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Lonza (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. GenScript (China)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. BioLegend (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Omega BioTek (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Dovetail Genomics (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Atlas Antibodies (Sweden)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Primary Antibodies Sale, by Type, Application, End-users, Technology, Research Area, Source and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Primary Antibodies (Value)
      • 7.2.1. Global Primary Antibodies by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Polyclonal Antibodies
      • 7.2.2. Global Primary Antibodies by: Application (Value)
        • 7.2.2.1. Proteomics
        • 7.2.2.2. Drug Development
        • 7.2.2.3. Genomics
      • 7.2.3. Global Primary Antibodies by: End-users (Value)
        • 7.2.3.1. Pharmaceutical and Biotechnological Companies
        • 7.2.3.2. Academic and Research Institutes
        • 7.2.3.3. Contract Research Organizations
      • 7.2.4. Global Primary Antibodies by: Technology (Value)
        • 7.2.4.1. Immunohistochemistry
        • 7.2.4.2. Immunofluorescence
        • 7.2.4.3. Western Blotting
        • 7.2.4.4. Flow Cytometry
        • 7.2.4.5. Immunoprecipitation
        • 7.2.4.6. ELISA
        • 7.2.4.7. Other Technologies
      • 7.2.5. Global Primary Antibodies by: Research Area (Value)
        • 7.2.5.1. Infectious Diseases
        • 7.2.5.2. Immunology
        • 7.2.5.3. Oncology
        • 7.2.5.4. Stem Cells
        • 7.2.5.5. Neurobiology
        • 7.2.5.6. Others
      • 7.2.6. Global Primary Antibodies by: Source (Value)
        • 7.2.6.1. Mouse
        • 7.2.6.2. Rabbit
        • 7.2.6.3. Goat
        • 7.2.6.4. Other Sources
      • 7.2.7. Global Primary Antibodies Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Primary Antibodies: by Type(USD Million)
  • Table 2. Primary Antibodies Monoclonal Antibodies , by Region USD Million (2015-2020)
  • Table 3. Primary Antibodies Polyclonal Antibodies , by Region USD Million (2015-2020)
  • Table 4. Primary Antibodies: by Application(USD Million)
  • Table 5. Primary Antibodies Proteomics , by Region USD Million (2015-2020)
  • Table 6. Primary Antibodies Drug Development , by Region USD Million (2015-2020)
  • Table 7. Primary Antibodies Genomics , by Region USD Million (2015-2020)
  • Table 8. Primary Antibodies: by End-users(USD Million)
  • Table 9. Primary Antibodies Pharmaceutical and Biotechnological Companies , by Region USD Million (2015-2020)
  • Table 10. Primary Antibodies Academic and Research Institutes , by Region USD Million (2015-2020)
  • Table 11. Primary Antibodies Contract Research Organizations , by Region USD Million (2015-2020)
  • Table 12. Primary Antibodies: by Technology(USD Million)
  • Table 13. Primary Antibodies Immunohistochemistry , by Region USD Million (2015-2020)
  • Table 14. Primary Antibodies Immunofluorescence , by Region USD Million (2015-2020)
  • Table 15. Primary Antibodies Western Blotting , by Region USD Million (2015-2020)
  • Table 16. Primary Antibodies Flow Cytometry , by Region USD Million (2015-2020)
  • Table 17. Primary Antibodies Immunoprecipitation , by Region USD Million (2015-2020)
  • Table 18. Primary Antibodies ELISA , by Region USD Million (2015-2020)
  • Table 19. Primary Antibodies Other Technologies , by Region USD Million (2015-2020)
  • Table 20. Primary Antibodies: by Research Area(USD Million)
  • Table 21. Primary Antibodies Infectious Diseases , by Region USD Million (2015-2020)
  • Table 22. Primary Antibodies Immunology , by Region USD Million (2015-2020)
  • Table 23. Primary Antibodies Oncology , by Region USD Million (2015-2020)
  • Table 24. Primary Antibodies Stem Cells , by Region USD Million (2015-2020)
  • Table 25. Primary Antibodies Neurobiology , by Region USD Million (2015-2020)
  • Table 26. Primary Antibodies Others , by Region USD Million (2015-2020)
  • Table 27. Primary Antibodies: by Source(USD Million)
  • Table 28. Primary Antibodies Mouse , by Region USD Million (2015-2020)
  • Table 29. Primary Antibodies Rabbit , by Region USD Million (2015-2020)
  • Table 30. Primary Antibodies Goat , by Region USD Million (2015-2020)
  • Table 31. Primary Antibodies Other Sources , by Region USD Million (2015-2020)
  • Table 32. South America Primary Antibodies, by Country USD Million (2015-2020)
  • Table 33. South America Primary Antibodies, by Type USD Million (2015-2020)
  • Table 34. South America Primary Antibodies, by Application USD Million (2015-2020)
  • Table 35. South America Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 36. South America Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 37. South America Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 38. South America Primary Antibodies, by Source USD Million (2015-2020)
  • Table 39. Brazil Primary Antibodies, by Type USD Million (2015-2020)
  • Table 40. Brazil Primary Antibodies, by Application USD Million (2015-2020)
  • Table 41. Brazil Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 42. Brazil Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 43. Brazil Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 44. Brazil Primary Antibodies, by Source USD Million (2015-2020)
  • Table 45. Argentina Primary Antibodies, by Type USD Million (2015-2020)
  • Table 46. Argentina Primary Antibodies, by Application USD Million (2015-2020)
  • Table 47. Argentina Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 48. Argentina Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 49. Argentina Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 50. Argentina Primary Antibodies, by Source USD Million (2015-2020)
  • Table 51. Rest of South America Primary Antibodies, by Type USD Million (2015-2020)
  • Table 52. Rest of South America Primary Antibodies, by Application USD Million (2015-2020)
  • Table 53. Rest of South America Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 54. Rest of South America Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 55. Rest of South America Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 56. Rest of South America Primary Antibodies, by Source USD Million (2015-2020)
  • Table 57. Asia Pacific Primary Antibodies, by Country USD Million (2015-2020)
  • Table 58. Asia Pacific Primary Antibodies, by Type USD Million (2015-2020)
  • Table 59. Asia Pacific Primary Antibodies, by Application USD Million (2015-2020)
  • Table 60. Asia Pacific Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 61. Asia Pacific Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 62. Asia Pacific Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 63. Asia Pacific Primary Antibodies, by Source USD Million (2015-2020)
  • Table 64. China Primary Antibodies, by Type USD Million (2015-2020)
  • Table 65. China Primary Antibodies, by Application USD Million (2015-2020)
  • Table 66. China Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 67. China Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 68. China Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 69. China Primary Antibodies, by Source USD Million (2015-2020)
  • Table 70. Japan Primary Antibodies, by Type USD Million (2015-2020)
  • Table 71. Japan Primary Antibodies, by Application USD Million (2015-2020)
  • Table 72. Japan Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 73. Japan Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 74. Japan Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 75. Japan Primary Antibodies, by Source USD Million (2015-2020)
  • Table 76. India Primary Antibodies, by Type USD Million (2015-2020)
  • Table 77. India Primary Antibodies, by Application USD Million (2015-2020)
  • Table 78. India Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 79. India Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 80. India Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 81. India Primary Antibodies, by Source USD Million (2015-2020)
  • Table 82. South Korea Primary Antibodies, by Type USD Million (2015-2020)
  • Table 83. South Korea Primary Antibodies, by Application USD Million (2015-2020)
  • Table 84. South Korea Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 85. South Korea Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 86. South Korea Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 87. South Korea Primary Antibodies, by Source USD Million (2015-2020)
  • Table 88. Taiwan Primary Antibodies, by Type USD Million (2015-2020)
  • Table 89. Taiwan Primary Antibodies, by Application USD Million (2015-2020)
  • Table 90. Taiwan Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 91. Taiwan Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 92. Taiwan Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 93. Taiwan Primary Antibodies, by Source USD Million (2015-2020)
  • Table 94. Australia Primary Antibodies, by Type USD Million (2015-2020)
  • Table 95. Australia Primary Antibodies, by Application USD Million (2015-2020)
  • Table 96. Australia Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 97. Australia Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 98. Australia Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 99. Australia Primary Antibodies, by Source USD Million (2015-2020)
  • Table 100. Rest of Asia-Pacific Primary Antibodies, by Type USD Million (2015-2020)
  • Table 101. Rest of Asia-Pacific Primary Antibodies, by Application USD Million (2015-2020)
  • Table 102. Rest of Asia-Pacific Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 103. Rest of Asia-Pacific Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 104. Rest of Asia-Pacific Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 105. Rest of Asia-Pacific Primary Antibodies, by Source USD Million (2015-2020)
  • Table 106. Europe Primary Antibodies, by Country USD Million (2015-2020)
  • Table 107. Europe Primary Antibodies, by Type USD Million (2015-2020)
  • Table 108. Europe Primary Antibodies, by Application USD Million (2015-2020)
  • Table 109. Europe Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 110. Europe Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 111. Europe Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 112. Europe Primary Antibodies, by Source USD Million (2015-2020)
  • Table 113. Germany Primary Antibodies, by Type USD Million (2015-2020)
  • Table 114. Germany Primary Antibodies, by Application USD Million (2015-2020)
  • Table 115. Germany Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 116. Germany Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 117. Germany Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 118. Germany Primary Antibodies, by Source USD Million (2015-2020)
  • Table 119. France Primary Antibodies, by Type USD Million (2015-2020)
  • Table 120. France Primary Antibodies, by Application USD Million (2015-2020)
  • Table 121. France Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 122. France Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 123. France Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 124. France Primary Antibodies, by Source USD Million (2015-2020)
  • Table 125. Italy Primary Antibodies, by Type USD Million (2015-2020)
  • Table 126. Italy Primary Antibodies, by Application USD Million (2015-2020)
  • Table 127. Italy Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 128. Italy Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 129. Italy Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 130. Italy Primary Antibodies, by Source USD Million (2015-2020)
  • Table 131. United Kingdom Primary Antibodies, by Type USD Million (2015-2020)
  • Table 132. United Kingdom Primary Antibodies, by Application USD Million (2015-2020)
  • Table 133. United Kingdom Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 134. United Kingdom Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 135. United Kingdom Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 136. United Kingdom Primary Antibodies, by Source USD Million (2015-2020)
  • Table 137. Netherlands Primary Antibodies, by Type USD Million (2015-2020)
  • Table 138. Netherlands Primary Antibodies, by Application USD Million (2015-2020)
  • Table 139. Netherlands Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 140. Netherlands Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 141. Netherlands Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 142. Netherlands Primary Antibodies, by Source USD Million (2015-2020)
  • Table 143. Rest of Europe Primary Antibodies, by Type USD Million (2015-2020)
  • Table 144. Rest of Europe Primary Antibodies, by Application USD Million (2015-2020)
  • Table 145. Rest of Europe Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 146. Rest of Europe Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 147. Rest of Europe Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 148. Rest of Europe Primary Antibodies, by Source USD Million (2015-2020)
  • Table 149. MEA Primary Antibodies, by Country USD Million (2015-2020)
  • Table 150. MEA Primary Antibodies, by Type USD Million (2015-2020)
  • Table 151. MEA Primary Antibodies, by Application USD Million (2015-2020)
  • Table 152. MEA Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 153. MEA Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 154. MEA Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 155. MEA Primary Antibodies, by Source USD Million (2015-2020)
  • Table 156. Middle East Primary Antibodies, by Type USD Million (2015-2020)
  • Table 157. Middle East Primary Antibodies, by Application USD Million (2015-2020)
  • Table 158. Middle East Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 159. Middle East Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 160. Middle East Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 161. Middle East Primary Antibodies, by Source USD Million (2015-2020)
  • Table 162. Africa Primary Antibodies, by Type USD Million (2015-2020)
  • Table 163. Africa Primary Antibodies, by Application USD Million (2015-2020)
  • Table 164. Africa Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 165. Africa Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 166. Africa Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 167. Africa Primary Antibodies, by Source USD Million (2015-2020)
  • Table 168. North America Primary Antibodies, by Country USD Million (2015-2020)
  • Table 169. North America Primary Antibodies, by Type USD Million (2015-2020)
  • Table 170. North America Primary Antibodies, by Application USD Million (2015-2020)
  • Table 171. North America Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 172. North America Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 173. North America Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 174. North America Primary Antibodies, by Source USD Million (2015-2020)
  • Table 175. United States Primary Antibodies, by Type USD Million (2015-2020)
  • Table 176. United States Primary Antibodies, by Application USD Million (2015-2020)
  • Table 177. United States Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 178. United States Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 179. United States Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 180. United States Primary Antibodies, by Source USD Million (2015-2020)
  • Table 181. Canada Primary Antibodies, by Type USD Million (2015-2020)
  • Table 182. Canada Primary Antibodies, by Application USD Million (2015-2020)
  • Table 183. Canada Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 184. Canada Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 185. Canada Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 186. Canada Primary Antibodies, by Source USD Million (2015-2020)
  • Table 187. Mexico Primary Antibodies, by Type USD Million (2015-2020)
  • Table 188. Mexico Primary Antibodies, by Application USD Million (2015-2020)
  • Table 189. Mexico Primary Antibodies, by End-users USD Million (2015-2020)
  • Table 190. Mexico Primary Antibodies, by Technology USD Million (2015-2020)
  • Table 191. Mexico Primary Antibodies, by Research Area USD Million (2015-2020)
  • Table 192. Mexico Primary Antibodies, by Source USD Million (2015-2020)
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Primary Antibodies: by Type(USD Million)
  • Table 210. Primary Antibodies Monoclonal Antibodies , by Region USD Million (2021-2026)
  • Table 211. Primary Antibodies Polyclonal Antibodies , by Region USD Million (2021-2026)
  • Table 212. Primary Antibodies: by Application(USD Million)
  • Table 213. Primary Antibodies Proteomics , by Region USD Million (2021-2026)
  • Table 214. Primary Antibodies Drug Development , by Region USD Million (2021-2026)
  • Table 215. Primary Antibodies Genomics , by Region USD Million (2021-2026)
  • Table 216. Primary Antibodies: by End-users(USD Million)
  • Table 217. Primary Antibodies Pharmaceutical and Biotechnological Companies , by Region USD Million (2021-2026)
  • Table 218. Primary Antibodies Academic and Research Institutes , by Region USD Million (2021-2026)
  • Table 219. Primary Antibodies Contract Research Organizations , by Region USD Million (2021-2026)
  • Table 220. Primary Antibodies: by Technology(USD Million)
  • Table 221. Primary Antibodies Immunohistochemistry , by Region USD Million (2021-2026)
  • Table 222. Primary Antibodies Immunofluorescence , by Region USD Million (2021-2026)
  • Table 223. Primary Antibodies Western Blotting , by Region USD Million (2021-2026)
  • Table 224. Primary Antibodies Flow Cytometry , by Region USD Million (2021-2026)
  • Table 225. Primary Antibodies Immunoprecipitation , by Region USD Million (2021-2026)
  • Table 226. Primary Antibodies ELISA , by Region USD Million (2021-2026)
  • Table 227. Primary Antibodies Other Technologies , by Region USD Million (2021-2026)
  • Table 228. Primary Antibodies: by Research Area(USD Million)
  • Table 229. Primary Antibodies Infectious Diseases , by Region USD Million (2021-2026)
  • Table 230. Primary Antibodies Immunology , by Region USD Million (2021-2026)
  • Table 231. Primary Antibodies Oncology , by Region USD Million (2021-2026)
  • Table 232. Primary Antibodies Stem Cells , by Region USD Million (2021-2026)
  • Table 233. Primary Antibodies Neurobiology , by Region USD Million (2021-2026)
  • Table 234. Primary Antibodies Others , by Region USD Million (2021-2026)
  • Table 235. Primary Antibodies: by Source(USD Million)
  • Table 236. Primary Antibodies Mouse , by Region USD Million (2021-2026)
  • Table 237. Primary Antibodies Rabbit , by Region USD Million (2021-2026)
  • Table 238. Primary Antibodies Goat , by Region USD Million (2021-2026)
  • Table 239. Primary Antibodies Other Sources , by Region USD Million (2021-2026)
  • Table 240. South America Primary Antibodies, by Country USD Million (2021-2026)
  • Table 241. South America Primary Antibodies, by Type USD Million (2021-2026)
  • Table 242. South America Primary Antibodies, by Application USD Million (2021-2026)
  • Table 243. South America Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 244. South America Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 245. South America Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 246. South America Primary Antibodies, by Source USD Million (2021-2026)
  • Table 247. Brazil Primary Antibodies, by Type USD Million (2021-2026)
  • Table 248. Brazil Primary Antibodies, by Application USD Million (2021-2026)
  • Table 249. Brazil Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 250. Brazil Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 251. Brazil Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 252. Brazil Primary Antibodies, by Source USD Million (2021-2026)
  • Table 253. Argentina Primary Antibodies, by Type USD Million (2021-2026)
  • Table 254. Argentina Primary Antibodies, by Application USD Million (2021-2026)
  • Table 255. Argentina Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 256. Argentina Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 257. Argentina Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 258. Argentina Primary Antibodies, by Source USD Million (2021-2026)
  • Table 259. Rest of South America Primary Antibodies, by Type USD Million (2021-2026)
  • Table 260. Rest of South America Primary Antibodies, by Application USD Million (2021-2026)
  • Table 261. Rest of South America Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 262. Rest of South America Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 263. Rest of South America Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 264. Rest of South America Primary Antibodies, by Source USD Million (2021-2026)
  • Table 265. Asia Pacific Primary Antibodies, by Country USD Million (2021-2026)
  • Table 266. Asia Pacific Primary Antibodies, by Type USD Million (2021-2026)
  • Table 267. Asia Pacific Primary Antibodies, by Application USD Million (2021-2026)
  • Table 268. Asia Pacific Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 269. Asia Pacific Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 270. Asia Pacific Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 271. Asia Pacific Primary Antibodies, by Source USD Million (2021-2026)
  • Table 272. China Primary Antibodies, by Type USD Million (2021-2026)
  • Table 273. China Primary Antibodies, by Application USD Million (2021-2026)
  • Table 274. China Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 275. China Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 276. China Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 277. China Primary Antibodies, by Source USD Million (2021-2026)
  • Table 278. Japan Primary Antibodies, by Type USD Million (2021-2026)
  • Table 279. Japan Primary Antibodies, by Application USD Million (2021-2026)
  • Table 280. Japan Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 281. Japan Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 282. Japan Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 283. Japan Primary Antibodies, by Source USD Million (2021-2026)
  • Table 284. India Primary Antibodies, by Type USD Million (2021-2026)
  • Table 285. India Primary Antibodies, by Application USD Million (2021-2026)
  • Table 286. India Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 287. India Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 288. India Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 289. India Primary Antibodies, by Source USD Million (2021-2026)
  • Table 290. South Korea Primary Antibodies, by Type USD Million (2021-2026)
  • Table 291. South Korea Primary Antibodies, by Application USD Million (2021-2026)
  • Table 292. South Korea Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 293. South Korea Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 294. South Korea Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 295. South Korea Primary Antibodies, by Source USD Million (2021-2026)
  • Table 296. Taiwan Primary Antibodies, by Type USD Million (2021-2026)
  • Table 297. Taiwan Primary Antibodies, by Application USD Million (2021-2026)
  • Table 298. Taiwan Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 299. Taiwan Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 300. Taiwan Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 301. Taiwan Primary Antibodies, by Source USD Million (2021-2026)
  • Table 302. Australia Primary Antibodies, by Type USD Million (2021-2026)
  • Table 303. Australia Primary Antibodies, by Application USD Million (2021-2026)
  • Table 304. Australia Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 305. Australia Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 306. Australia Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 307. Australia Primary Antibodies, by Source USD Million (2021-2026)
  • Table 308. Rest of Asia-Pacific Primary Antibodies, by Type USD Million (2021-2026)
  • Table 309. Rest of Asia-Pacific Primary Antibodies, by Application USD Million (2021-2026)
  • Table 310. Rest of Asia-Pacific Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 311. Rest of Asia-Pacific Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 312. Rest of Asia-Pacific Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 313. Rest of Asia-Pacific Primary Antibodies, by Source USD Million (2021-2026)
  • Table 314. Europe Primary Antibodies, by Country USD Million (2021-2026)
  • Table 315. Europe Primary Antibodies, by Type USD Million (2021-2026)
  • Table 316. Europe Primary Antibodies, by Application USD Million (2021-2026)
  • Table 317. Europe Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 318. Europe Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 319. Europe Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 320. Europe Primary Antibodies, by Source USD Million (2021-2026)
  • Table 321. Germany Primary Antibodies, by Type USD Million (2021-2026)
  • Table 322. Germany Primary Antibodies, by Application USD Million (2021-2026)
  • Table 323. Germany Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 324. Germany Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 325. Germany Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 326. Germany Primary Antibodies, by Source USD Million (2021-2026)
  • Table 327. France Primary Antibodies, by Type USD Million (2021-2026)
  • Table 328. France Primary Antibodies, by Application USD Million (2021-2026)
  • Table 329. France Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 330. France Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 331. France Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 332. France Primary Antibodies, by Source USD Million (2021-2026)
  • Table 333. Italy Primary Antibodies, by Type USD Million (2021-2026)
  • Table 334. Italy Primary Antibodies, by Application USD Million (2021-2026)
  • Table 335. Italy Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 336. Italy Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 337. Italy Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 338. Italy Primary Antibodies, by Source USD Million (2021-2026)
  • Table 339. United Kingdom Primary Antibodies, by Type USD Million (2021-2026)
  • Table 340. United Kingdom Primary Antibodies, by Application USD Million (2021-2026)
  • Table 341. United Kingdom Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 342. United Kingdom Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 343. United Kingdom Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 344. United Kingdom Primary Antibodies, by Source USD Million (2021-2026)
  • Table 345. Netherlands Primary Antibodies, by Type USD Million (2021-2026)
  • Table 346. Netherlands Primary Antibodies, by Application USD Million (2021-2026)
  • Table 347. Netherlands Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 348. Netherlands Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 349. Netherlands Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 350. Netherlands Primary Antibodies, by Source USD Million (2021-2026)
  • Table 351. Rest of Europe Primary Antibodies, by Type USD Million (2021-2026)
  • Table 352. Rest of Europe Primary Antibodies, by Application USD Million (2021-2026)
  • Table 353. Rest of Europe Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 354. Rest of Europe Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 355. Rest of Europe Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 356. Rest of Europe Primary Antibodies, by Source USD Million (2021-2026)
  • Table 357. MEA Primary Antibodies, by Country USD Million (2021-2026)
  • Table 358. MEA Primary Antibodies, by Type USD Million (2021-2026)
  • Table 359. MEA Primary Antibodies, by Application USD Million (2021-2026)
  • Table 360. MEA Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 361. MEA Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 362. MEA Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 363. MEA Primary Antibodies, by Source USD Million (2021-2026)
  • Table 364. Middle East Primary Antibodies, by Type USD Million (2021-2026)
  • Table 365. Middle East Primary Antibodies, by Application USD Million (2021-2026)
  • Table 366. Middle East Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 367. Middle East Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 368. Middle East Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 369. Middle East Primary Antibodies, by Source USD Million (2021-2026)
  • Table 370. Africa Primary Antibodies, by Type USD Million (2021-2026)
  • Table 371. Africa Primary Antibodies, by Application USD Million (2021-2026)
  • Table 372. Africa Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 373. Africa Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 374. Africa Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 375. Africa Primary Antibodies, by Source USD Million (2021-2026)
  • Table 376. North America Primary Antibodies, by Country USD Million (2021-2026)
  • Table 377. North America Primary Antibodies, by Type USD Million (2021-2026)
  • Table 378. North America Primary Antibodies, by Application USD Million (2021-2026)
  • Table 379. North America Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 380. North America Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 381. North America Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 382. North America Primary Antibodies, by Source USD Million (2021-2026)
  • Table 383. United States Primary Antibodies, by Type USD Million (2021-2026)
  • Table 384. United States Primary Antibodies, by Application USD Million (2021-2026)
  • Table 385. United States Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 386. United States Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 387. United States Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 388. United States Primary Antibodies, by Source USD Million (2021-2026)
  • Table 389. Canada Primary Antibodies, by Type USD Million (2021-2026)
  • Table 390. Canada Primary Antibodies, by Application USD Million (2021-2026)
  • Table 391. Canada Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 392. Canada Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 393. Canada Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 394. Canada Primary Antibodies, by Source USD Million (2021-2026)
  • Table 395. Mexico Primary Antibodies, by Type USD Million (2021-2026)
  • Table 396. Mexico Primary Antibodies, by Application USD Million (2021-2026)
  • Table 397. Mexico Primary Antibodies, by End-users USD Million (2021-2026)
  • Table 398. Mexico Primary Antibodies, by Technology USD Million (2021-2026)
  • Table 399. Mexico Primary Antibodies, by Research Area USD Million (2021-2026)
  • Table 400. Mexico Primary Antibodies, by Source USD Million (2021-2026)
  • Table 401. Research Programs/Design for This Report
  • Table 402. Key Data Information from Secondary Sources
  • Table 403. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Primary Antibodies: by Type USD Million (2015-2020)
  • Figure 5. Global Primary Antibodies: by Application USD Million (2015-2020)
  • Figure 6. Global Primary Antibodies: by End-users USD Million (2015-2020)
  • Figure 7. Global Primary Antibodies: by Technology USD Million (2015-2020)
  • Figure 8. Global Primary Antibodies: by Research Area USD Million (2015-2020)
  • Figure 9. Global Primary Antibodies: by Source USD Million (2015-2020)
  • Figure 10. South America Primary Antibodies Share (%), by Country
  • Figure 11. Asia Pacific Primary Antibodies Share (%), by Country
  • Figure 12. Europe Primary Antibodies Share (%), by Country
  • Figure 13. MEA Primary Antibodies Share (%), by Country
  • Figure 14. North America Primary Antibodies Share (%), by Country
  • Figure 15. Global Primary Antibodies share by Players 2020 (%)
  • Figure 16. Global Primary Antibodies share by Players (Top 3) 2020(%)
  • Figure 17. Global Primary Antibodies share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Becton, Dickinson and Company (United States) Revenue: by Geography 2020
  • Figure 21. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bio-Rad Laboratories (United States) Revenue: by Geography 2020
  • Figure 23. Cell Signaling Technology (United States) Revenue, Net Income and Gross profit
  • Figure 24. Cell Signaling Technology (United States) Revenue: by Geography 2020
  • Figure 25. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 26. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 27. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Merck Group (Germany) Revenue: by Geography 2020
  • Figure 29. Abcam plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Abcam plc (United Kingdom) Revenue: by Geography 2020
  • Figure 31. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2020
  • Figure 33. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 34. Danaher Corporation (United States) Revenue: by Geography 2020
  • Figure 35. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 36. Agilent Technologies (United States) Revenue: by Geography 2020
  • Figure 37. PerkinElmer (United States) Revenue, Net Income and Gross profit
  • Figure 38. PerkinElmer (United States) Revenue: by Geography 2020
  • Figure 39. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. Lonza (Switzerland) Revenue: by Geography 2020
  • Figure 41. GenScript (China) Revenue, Net Income and Gross profit
  • Figure 42. GenScript (China) Revenue: by Geography 2020
  • Figure 43. BioLegend (United States) Revenue, Net Income and Gross profit
  • Figure 44. BioLegend (United States) Revenue: by Geography 2020
  • Figure 45. Omega BioTek (United States) Revenue, Net Income and Gross profit
  • Figure 46. Omega BioTek (United States) Revenue: by Geography 2020
  • Figure 47. Dovetail Genomics (United States) Revenue, Net Income and Gross profit
  • Figure 48. Dovetail Genomics (United States) Revenue: by Geography 2020
  • Figure 49. Atlas Antibodies (Sweden) Revenue, Net Income and Gross profit
  • Figure 50. Atlas Antibodies (Sweden) Revenue: by Geography 2020
  • Figure 51. Global Primary Antibodies: by Type USD Million (2021-2026)
  • Figure 52. Global Primary Antibodies: by Application USD Million (2021-2026)
  • Figure 53. Global Primary Antibodies: by End-users USD Million (2021-2026)
  • Figure 54. Global Primary Antibodies: by Technology USD Million (2021-2026)
  • Figure 55. Global Primary Antibodies: by Research Area USD Million (2021-2026)
  • Figure 56. Global Primary Antibodies: by Source USD Million (2021-2026)
  • Figure 57. South America Primary Antibodies Share (%), by Country
  • Figure 58. Asia Pacific Primary Antibodies Share (%), by Country
  • Figure 59. Europe Primary Antibodies Share (%), by Country
  • Figure 60. MEA Primary Antibodies Share (%), by Country
  • Figure 61. North America Primary Antibodies Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Becton, Dickinson and Company (United States)
  • Bio-Rad Laboratories (United States)
  • Cell Signaling Technology (United States)
  • Thermo Fisher Scientific (United States)
  • Merck Group (Germany)
  • Abcam plc (United Kingdom)
  • F. Hoffmann-La Roche (Switzerland)
  • Danaher Corporation (United States)
  • Agilent Technologies (United States)
  • PerkinElmer (United States)
  • Lonza (Switzerland)
  • GenScript (China)
  • BioLegend (United States)
  • Omega BioTek (United States)
  • Dovetail Genomics (United States)
  • Atlas Antibodies (Sweden)
Additional players considered in the study are as follows:
Illumia (United States) , ImmonoPresice Antibodies (Canada) , Fujirebio (Sweden) , Analytik Jena AG (Germany)
Select User Access Type

Key Highlights of Report


Feb 2021 201 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Primary Antibodies Quantitative research analysis
Global Primary Antibodies Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rise in the Number of Stell Cell and Neurology Research " is seen as one of major growth factors of Primary Antibodies Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Primary Antibodies Report?

Have a Query? Click Here

Other Related Reports

Anticoccidial Drugs Comprehensive Study by Type (Antibiotic Anticoccidials, Ionophore Anticoccidials, Chemical Derivative Anticoccidials), Application (Poultry, Swine, Fish, Cattle, Companion Animals...
$ 3450
Erectile Dysfunction Drugs Comprehensive Study by Type (Existing Drugs, Pipeline Drugs), Distribution Channel (Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce), Pipel...
$ 3750
Tea Capsules Comprehensive Study by Type (Red Tea Capsules, Oolong Tea Capsules, Black Tea Capsules, Yellow Tea Capsules), Application (Residential, Commercial), Category (Children, Adults), Distribu...
$ 3450
Lyophilized Antivenins Comprehensive Study by Type (Neurotoxin, Blood Toxin, Mixed Toxin), Application (Hospital, Medical Center), Route of Administration (Intravenous Injection, Infusion), Strength ...
$ 3500
Vitamin B9 Comprehensive Study by Application (Food & beverages, Pharmaceuticals, Nutraceuticals, Others), Disease (Alzheimer's, Memory Loss, Weak Bones, Hearing Loss, Sleep Problems, Others), Source...
$ 3750
Capsule Polisher Comprehensive Study by Type (With Metal Detector, With Sorter, Others), Application (Pharmaceutical, Nutraceutical, Others), Capacity (Upto 50,000/hr., 50,000 – 80,000/hr., 80,000 – ...
$ 3450